Journal
CELL DEATH & DISEASE
Volume 11, Issue 5, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41419-020-2542-9
Keywords
-
Categories
Funding
- National Natural Science Foundation of China (NSFC) [81900317, 91839101]
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China [19KJB310013]
- Introduction Project of Clinical Medicine Expert Team for Suzhou [SZYJTD201704]
- National Clinical Key Specialty of Cardiovascular Surgery
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) are derived from a wide range of sources and easily isolated and cultured. MSCs have the capacity for in vitro amplification and self-renewal, low immunogenicity and immunomodulatory properties, and under certain conditions, MSCs can be differentiated into a variety of cells. In the cardiovascular system, MSCs can protect the myocardium by reducing the level of inflammation, promoting the differentiation of myocardial cells around infarct areas and angiogenesis, increasing apoptosis resistance, and inhibiting fibrosis, which are ideal qualities for cardiovascular repair. Preclinical studies have shown that MSCs can be transplanted and improve cardiac repair, but challenges, such as their low rate of migration to the ischemic myocardium, low tissue retention, and low survival rate after transplantation, remain. This article reviews the potential and methods of MSC transplantation in the treatment of cardiovascular diseases (CVDs) and the challenges of the clinical use of MSCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available